| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-039 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于聘任副总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 年 5 月 16 日 谭小勇，男，1984 年 10 月出生，中国国籍，无境外永久居留权，硕士研究 生学历。2008 年 2 月至 2009 年 3 月，任上海上体活力体育文化服务有限公司市 场推广；2009 年 4 月至 2009 年 8 月，任上海锐聪实验室设备有限公司业务员； 2010 年 11 月至 2019 年 11 月，任上海永叶生物科技有限公司执行董事兼总经理； 2011 年 11 月至 2019 年 8 月，任上海先浩国际贸易有限公司执行董事兼总经理； 2009 年 8 月至今，任上海源叶生物科技有限公司执行董事，总经理；2018 年 10 月至今，任北京源叶生物科技有限公司董事,财务负责人,经理；2020 年 ...

上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 2024 年年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 上海市锦天城律师事务所（以下简称"本所"）接受上海阿拉丁生化科技股 份有限公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以下 简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《上市公司股东大会规则》等法律、法规、规章和其他规范性文 件以及《上海阿拉丁生化科技股份有限公司章程》（以下简称"《公司章程》"）的 有关规定，出具本法律意见书。 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 2024 年年度股东大会的 法律意见书 致：上海阿拉丁生化科技股份有限公司 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-038 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 59 | | --- | --- | | 普通股股东人数 | 59 | | 2、出席会议的股东所持有的表决权数量 | 135,857,273 | | 普通股股东所持有表决权数量 | 135,857,273 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 48.9778 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 48.9778 | （四） 表决方式是否符合《公司 ...

Investment Rating - The report does not provide specific investment ratings for the sub-industries within the pharmaceutical sector [3]. Core Insights - The life sciences upstream sector has experienced a significant recovery since September 24, 2024, with a 60% increase in the index, outperforming the pharmaceutical and biotechnology sectors by 40 percentage points [4][23]. - The sector is currently in a rebound phase after undergoing a clearing phase from mid-2022 to late 2024, characterized by supply-demand imbalances and subsequent recovery [20][23]. Supply Side Summary - The supply side is witnessing a turning point, with local products continuously upgrading to mid-to-high-end levels, aiming for global leadership [5]. - The overall capital expenditure depreciation has dropped to its lowest level in nearly six years, indicating a recovery in the supply chain [29]. - Companies are experiencing a gradual recovery in gross profit margins, with some, like Aladdin and Nanmo Biology, showing signs of improvement after hitting lows [34]. Demand Side Summary - Research institutions and large pharmaceutical companies are steadily increasing their R&D expenditures, with improved financing potentially stimulating high growth in smaller pharmaceutical companies [6]. - The recognition of domestic brands is increasing, accelerating the process of replacing foreign products, particularly in protein and culture media categories [6]. Related Companies - **Aopumai**: A leading domestic brand in culture media, with a comprehensive layout in "culture media + CRO + CDMO" [8]. - **Aladdin**: A domestic high-end research reagent brand, expected to contribute additional growth from overseas [8]. - **Baipusais**: A leading domestic player in recombinant proteins, with a turning point in performance [8]. - **Nuowei Zhan**: A leader in molecular biological reagents, benefiting from the domestic replacement trend [8]. - **Jian Kai Technology**: A leading domestic PEG company, with new product releases expected to open up growth space [8]. - **BGI Genomics**: Focused on domestic markets while expanding globally, optimistic about accelerating domestic replacements [8].

Core Viewpoint - The report summarizes the sponsorship and continuous supervision of Shanghai Aladdin Biochemical Technology Co., Ltd. by Western Securities for the issuance of convertible bonds to unspecified objects, highlighting the compliance with regulatory requirements and the company's operational adjustments during the process [1][2]. Group 1: Company Overview - Company Name: Shanghai Aladdin Biochemical Technology Co., Ltd. [2] - Securities Code: 688179.SH [2] - Registered Capital: 277,385,321 Yuan [2] - Registered Address: No. 809, Chuhua Branch Road, Fengxian District, Shanghai [2] - Legal Representative: Xu Jiuzhen [2] - Actual Controllers: Xu Jiuzhen, Zhao Liping [2] - Secretary of the Board: Zhao Xin'an [2] - Type of Securities Issuance: Convertible bonds to unspecified objects [2] - Listing Date: April 12, 2022 [2] - Listing Location: Shanghai Stock Exchange [2] Group 2: Sponsorship Work Overview - The sponsor conducted due diligence and prepared application documents, ensuring compliance with laws and regulations [3][4]. - After obtaining approval from the China Securities Regulatory Commission (CSRC), the sponsor submitted the necessary documents for issuance and listing [3]. Group 3: Continuous Supervision Phase - The sponsor ensured the company adhered to operational norms, commitments, and information disclosure obligations during the continuous supervision phase [4]. - The company adjusted investment amounts and internal investment structures for certain fundraising projects, ensuring no impact on main business operations [5][6]. Group 4: Major Events and Handling - The company approved adjustments to investment amounts for specific projects, reflecting the need for efficient use of raised funds without altering the total investment amount [5]. - The adjustments were approved by the board, supervisory board, shareholders' meeting, and bondholders' meeting, with the sponsor providing verification opinions [5][6]. Group 5: Company Cooperation with Sponsorship - The company provided necessary documents and information for the issuance process, ensuring their authenticity and completeness [6]. - During the continuous supervision phase, the company maintained compliance with regulations and promptly communicated significant events to the sponsor [6][7]. Group 6: Conclusion on Information Disclosure - The sponsor reviewed the company's information disclosure documents, confirming compliance with relevant regulations and ensuring timely and accurate disclosures [7][8]. - The company adhered to the special account storage system for raised funds, with no violations in the use of these funds [8]. Group 7: Remaining Matters - As of December 31, 2024, the company has not fully utilized the raised funds from the convertible bond issuance, and the sponsor will continue to supervise the remaining fund usage and conversion matters [8].

关于上海阿拉丁生化科技股份有限公司 向不特定对象发行可转换公司债券之保荐总结报告书 保荐人（主承销商） 西部证券股份有限公司 （陕西省西安市新城区东新街 319 号 8 幢 10000 室） 西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 向不特定对象发行可转换公司债券之保荐总结报告书 一、保荐人及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐人及保荐代表人对其真实性、准确性、完整性承担法律 责任。 2、保荐人及保荐代表人自愿接受中国证监会对保荐总结报告书相关事项进 行的任何质询和调查。 3、保荐人及保荐代表人自愿接受中国证监会按照《证券发行上市保荐业务 管理办法》的有关规定采取的监管措施。 | 名称 | 西部证券股份有限公司 | | --- | --- | | 法定代表人 | 徐朝晖 | | 注册地址 | 陕西省西安市新城区东新街 号 幢 室 319 8 10000 | | 办公地址 | 陕西省西安市新城区东新街 号 幢 室 319 8 10000 | | 保荐代表人 | 滕晶、李晶 | 二、保荐人基本情况 联系电话 021-688869 ...

公司代码：688179 公司简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 2024 年年度股东大会 会议资料 中国·上海 2025 年 5 月 上海阿拉丁生化科技股份有限公司 2024 年年度股东大会 上海阿拉丁生化科技股份有限公司 2024 年年度股东大会 目录 | 2024 | 年年度股东大会会议须知 | 3 | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | 5 | | 2024 | 年年度股东大会会议议案 | 7 | | | 议案一：审议《关于<2024 | 年度董事会工作报告>的议案》 7 | | | 议案二：审议《关于<2024 | 年度监事会工作报告>的议案》 16 | | | 议案三：审议《关于<2024 | 年年度报告及其摘要>的议案》 20 | | | 议案四：审议《关于公司 | 2024 年年度利润分配及资本公积金转增股本方案 | | | 的议案》 | 21 | | | 议案五：审议《关于<2024 | 年度财务决算报告>的议案》 23 | | | 议案六：审议《关于<2025 | 年度财务预算报告>的议案 ...

Group 1: Haoyuan Pharmaceutical - Haoyuan Pharmaceutical emphasizes technological innovation as its core competitiveness, with plans to invest in R&D across multiple fields including anti-tumor and anti-viral areas in 2024 [1] - The company has completed the construction of a solid-phase platform for peptides, establishing a peptide CRO capability and developing over 600 compounds, along with a peptide drug production platform in Ma'anshan [1] - The molecular building block business is projected to achieve revenue of 420 million yuan in 2024, representing a year-on-year growth of 35.7%, with a reserve of 92,000 types of molecular building blocks and capabilities in customized R&D and global supply chain management [1] - Progress has been made in the construction of industrialization and CDMO bases in Jiangsu Qidong, Shandong Heze, Anhui Ma'anshan, and Chongqing, with some workshops already in operation [1] Group 2: Aladdin - Aladdin has achieved strong competitiveness through independent research and innovation, with several products realizing domestic substitution [2] - The company collaborates closely with Yuan Ye and Feipeng to share resources, expand business scale, and enhance overall competitiveness [2] - Cost control measures include promoting convertible bond conversions, optimizing inventory turnover, expanding overseas markets, and developing the biological reagent business [2] - Revenue growth in the life sciences segment is primarily driven by the merger with Yuan Ye Bio, which has increased sales of major life science products [2] - Both external and internal growth strategies are driving the company's development, with active research into potential acquisition projects [2] Group 3: Company Overview - Shanghai Panyao Asset Management Co., Ltd. was established on December 4, 2014, with a registered capital of 10 million yuan and holds a private equity license [3] - The firm focuses on long/short equity strategies and has issued over 100 products, with a cumulative registered scale exceeding 5 billion yuan [3] - Panyao Asset aims to manage financial wealth sustainably, emphasizing research-driven investment and a rigorous investment process [3] - The company seeks an ideal combination of top-down macro and industry allocation with bottom-up company selection in its investment strategy [3]

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover, and foster a sense of ownership among employees [1] - Recent strategic adjustments include clarifying strategy, aligning organizational design, building talent teams, and cultural development [1] - E-commerce initiatives involve inventory optimization, pricing adjustments, organizational restructuring, and product iteration [1] - The Yuze B5 series is planned as a key product line for JD.com [1] - The company aims for double-digit revenue growth this year and to turn profits around [1] - The long-term profit recovery is expected to follow a 1-2 year revenue growth, 2-3 year profit improvement, and 3-5 year profit margin targets [1] Group 2: Zai Lab - Zai Lab introduced its pipeline drugs ZG006, ZG005, and ZGGS18, highlighting their latest progress and future plans for R&D, commercialization, and internationalization over the next 3-5 years [2] - ZG006 is the world's first DLL3-expressing tumor tri-specific antibody, which has received clinical trial approval from NMPA and FDA, showing promising early efficacy [2] - ZG005 is among the first drugs in clinical research targeting the same pathway, with multiple clinical studies ongoing [2] - ZGGS18 has completed the I phase dose escalation in China and is currently in I/II phase clinical trials [2] - The company plans to continuously explore the commercialization potential of its existing and upcoming products to achieve sustained revenue growth [2] Group 3: Aladdin - Aladdin has achieved several domestic product replacements through independent R&D and innovation, enhancing its competitive edge [3] - The company collaborates with Yuan Ye and Fei Peng to share resources, expand business scale, and improve overall competitiveness [3] - Cost control measures include promoting convertible bond conversions, optimizing inventory turnover, and expanding overseas markets and biological reagent business [3] - Revenue growth in the life sciences sector is primarily driven by the merger with Yuan Ye Bio, increasing sales of major life science products [3] - Both external and internal growth strategies are driving the company's development, with active research into potential acquisition projects [3] Group 4: Company Overview - Shanghai Licheng Asset is one of the earliest established private equity management companies in China, focusing on growth stock investment with a safety margin approach [4] - The company has a complete and unique investment management knowledge system, with a team of 50 employees, nearly 30 of whom are professional research analysts [4] - The management scale has exceeded 10 billion yuan, specializing in secondary stock long strategies and PIPE strategies in the pharmaceutical, advanced manufacturing, and consumer sectors [4] - Licheng has consistently ranked high in long-term performance and has received multiple private equity awards [4]

上海阿拉丁生化科技股份有限公司 舆情管理制度 第一章 总则 第一条 为提高上海阿拉丁生化科技股份有限公司（以下简称"公司"）应 对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情 对公司股价、商业信誉及正常生产经营活动造成的影响，切实保护投资者合法 权益，根据相关法律法规、规范性文件和《上海阿拉丁生化科技股份有限公司 股份有限公司章程》（以下简称"公司章程"）等规定，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的 信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较大影响的事件信息。 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情（尤其是媒体质疑危机时）实行统一领导、统一 组织、快速反应、协同应对。 第四条 公司舆情管理工作由公司董事会统一领导和管理，董事长作为第一 责任人，负责领导各类舆情处理工作。必要时可成立舆情管理应急小组，由董 事长任组长，董事会秘书任副组长，其他高级管理 ...